Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

Mydecine finishes harvest and is preparing to export 20 kgs of psilocybin mushrooms from Jamaica to Canada for increased worldwide supply scale of cGMP nature-sourced psilocybin

DENVER, Dec. 08, 2020 (WORLD NEWSWIRE)– Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (” Mydecine” or the “Business’), an emerging biopharma and life sciences business dedicated to the research study, advancement, and approval of alternative nature-sourced restorative medication for mainstream usage, revealed that it has actually finished its very first industrial harvest of 20 kgs of psilocybin mushrooms at its research study and growing center in Jamaica. The Business is now preparing to export the harvest to its Canadian cGMP Center which has a Health Canada schedule 1 Dealership’s License connected to it, permitting legal import.

” We are happy to reveal the conclusion of our very first industrial harvest of natural psilocybin mushrooms,” stated Joshua Bartch, CEO and Chairman of Mydecine. “There is more research study required on these substances in order to much better comprehend the entourage impact experienced by clients which has actually revealed significantly reliable outcomes compared to single-molecule artificial psilocybin in initial research studies. As the market grows, the requirement for naturally happening psilocybin and access to big amounts of these particles will be vital and we are delighted to be the very first to advance this motion at scale.”

When gotten by the Business’s center in Canada, the psilocybin mushrooms will be drawn out, improved and become a cGMP end product for regulated restorative functions. Mydecine’s end product be offered for purchase by other certified organizations and business performing medical research study into the effectiveness of these substances to deal with numerous health conditions consisting of stress and anxiety, dependency, anxiety and PTSD. Parts of the harvest will likewise be utilized for Mydecine’s exclusive hereditary, pharmacology, and medical research study. The medical usage will be for the research studies and establishing procedures of psilocybin-assisted psychiatric therapy to deal with PTSD in veterans and other frontline employees.

About Mydecine Innovations Group
Mydecine Innovations Group ™ is a life sciences business devoted to establishing and advertising ingenious options for dealing with psychological health issue and boosting health and wellbeing. The business’s world-renowned medical and clinical board of advisers is advancing a robust R&D pipeline of psychedelic obtained therapies, unique substances, treatments, and managed drug shipment systems. Mydecine has unique access to a complete cGMP accredited pharmaceutical production center with the capability to import/export, extract, and evaluate natural and artificial psychedelic substances with complete federal government approval through Health Canada.

Discover More at: and follow us on Facebook, Twitter, and Instagram

Mydecine Innovations Group Media Contacts
Anne Donohoe/ Nick Opich
KCSA Strategic Communications
[email protected]/ [email protected]
212-896-1265/ 212-896-1206

On behalf of the Board of Directors:
Joshua Bartch, Ceo
[email protected]

Corp Interaction:
Charles Lee, Financier Relations
[email protected]
+1 720-277-9879

For additional details about Mydecine Innovations Group, Inc., please go to the Business’s profile on SEDAR at or go to the Business’s site at

The Canadian Securities Exchange has actually neither authorized nor disapproved the contents of this press release and accepts no duty for the adequacy or precision hereof. This press release includes positive declarations, which associate with future occasions or future efficiency and show management’s present expectations and presumptions. Such positive declarations show management’s present beliefs and are based upon presumptions made by and details presently offered to the Business. Readers are warned that these positive declarations are neither pledges nor warranties, and undergo dangers and unpredictabilities that might trigger future outcomes to vary materially from those anticipated consisting of, without restriction, the schedule and connection of funding, the capability of the Business to effectively safeguard and implement its copyright, the Business’s capability to bring its items to industrial production, continued development of the worldwide adaptive path medication, natural health items and digital health markets, and the dangers provided by the extremely managed and competitive market worrying the advancement, production, sale and usage of the Business’s items. Although the Business has actually tried to recognize essential aspects that might trigger real outcomes to vary materially from those included in positive details, there might be other aspects that trigger results not to be as expected, approximated or meant. There can be no guarantee that such details will show to be precise, as real outcomes and future occasions might vary materially from those expected in such details. These positive declarations are made since the date hereof and the Business does not presume any responsibility to upgrade or modify them to show brand-new occasions or situations conserve as needed under suitable securities legislation. This press release does not make up a deal to offer securities and the Business is not obtaining a deal to purchase securities in any jurisdiction in which such deal, solicitation or sale would be illegal previous to registration or certification under the securities laws of such jurisdiction. This press release does not make up a deal of securities for sale in the United States. These securities have not and will not be signed up under United States Securities Act of 1933, as changed, or any state securities laws and might not be provided or offered in the United States or to a U.S. Individual unless so signed up, or an exemption from registration is trusted.

Latest posts